ZA200800505B - Modified influenza virus for monitoring and improving vaccine efficiency - Google Patents

Modified influenza virus for monitoring and improving vaccine efficiency

Info

Publication number
ZA200800505B
ZA200800505B ZA200800505A ZA200800505A ZA200800505B ZA 200800505 B ZA200800505 B ZA 200800505B ZA 200800505 A ZA200800505 A ZA 200800505A ZA 200800505 A ZA200800505 A ZA 200800505A ZA 200800505 B ZA200800505 B ZA 200800505B
Authority
ZA
South Africa
Prior art keywords
monitoring
influenza virus
modified influenza
vaccine efficiency
improving vaccine
Prior art date
Application number
ZA200800505A
Other languages
English (en)
Inventor
Hoffmann Erich
Aleksandr S Lipatov
Robert G Webster
Richard J Webby
Elena A Govorkova
Original Assignee
St Jude Childrens Res Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by St Jude Childrens Res Hospital filed Critical St Jude Childrens Res Hospital
Publication of ZA200800505B publication Critical patent/ZA200800505B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1018—Orthomyxoviridae, e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16161—Methods of inactivation or attenuation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/11—Orthomyxoviridae, e.g. influenza virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
ZA200800505A 2005-08-04 2008-01-17 Modified influenza virus for monitoring and improving vaccine efficiency ZA200800505B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US70580805P 2005-08-04 2005-08-04

Publications (1)

Publication Number Publication Date
ZA200800505B true ZA200800505B (en) 2008-12-31

Family

ID=37727844

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200800505A ZA200800505B (en) 2005-08-04 2008-01-17 Modified influenza virus for monitoring and improving vaccine efficiency

Country Status (16)

Country Link
US (4) US7871626B2 (ja)
EP (1) EP1924281B1 (ja)
JP (2) JP5395430B2 (ja)
KR (1) KR101334047B1 (ja)
CN (2) CN101283099B (ja)
AU (1) AU2006278696B2 (ja)
BR (1) BRPI0614297A2 (ja)
CA (1) CA2617483C (ja)
ES (1) ES2728791T3 (ja)
HU (1) HUE043952T2 (ja)
PL (1) PL1924281T3 (ja)
RU (3) RU2480480C2 (ja)
SG (1) SG2014007934A (ja)
UA (1) UA94717C2 (ja)
WO (1) WO2007019094A2 (ja)
ZA (1) ZA200800505B (ja)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7871626B2 (en) 2005-08-04 2011-01-18 St. Jude Children's Research Hospital Modified influenza virus for monitoring and improving vaccine efficiency
EP1942924B1 (en) 2005-10-28 2012-02-01 Boehringer Ingelheim Vetmedica GmbH Use of vaccines for the treatment/prevention of the transmission of influenza pathogens between species
JP2010501074A (ja) * 2006-08-14 2010-01-14 マサチューセッツ・インスティテュート・オブ・テクノロジー グリカンのデータマイニングシステム
US8202967B2 (en) * 2006-10-27 2012-06-19 Boehringer Ingelheim Vetmedica, Inc. H5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use
CA2687147C (en) * 2007-05-11 2016-08-23 Temasek Life Sciences Laboratory Limited H5 subtype-specific binding proteins useful for h5 avian influenza diagnosis and surveillance
MX363240B (es) * 2007-06-25 2019-03-15 The Administrators Of The Tulane Educational Fund Composiciones que inhiben la influenza y métodos.
CA2615372A1 (en) 2007-07-13 2009-01-13 Marc-Andre D'aoust Influenza virus-like particles (vlps) comprising hemagglutinin
EP2610345B1 (en) 2007-11-27 2015-08-19 Medicago Inc. Recombinant influenza virus-like particles (VLPS) produced in transgenic plants expressing hemagglutinin
AU2009232503B2 (en) * 2008-04-01 2013-03-28 Innate Immunotherapeutics Limited Anti-infective agents and uses thereof
CN102165062B (zh) * 2008-07-18 2017-09-08 麦迪卡格公司 新的流感病毒免疫表位
HUE030520T2 (en) * 2008-11-28 2017-05-29 Statens Seruminstitut Optimized influenza vaccines
KR101145720B1 (ko) * 2009-06-23 2012-05-14 한밭대학교 산학협력단 안전성이 뛰어난 인플루엔자 바이러스 백신용 재조합 헤마글루티닌 단백질을 함유하는 생분해성 ｐｌｇａ 미립자의 제조 방법
SI2445928T1 (en) 2009-06-24 2018-05-31 Medicago Inc. HYPER PARTICULARS, SIMILAR VIRUSES OF GRIPE, WHICH HAVE EXPOSED HEMAGLUTININE
EP2448598B1 (en) * 2009-06-25 2016-03-30 MedImmune, LLC Swine influenza hemagglutinin variants
KR102115226B1 (ko) 2009-09-22 2020-05-27 메디카고 인코포레이티드 식물-유래 단백질의 제조방법
CN102095852A (zh) * 2010-11-24 2011-06-15 中国检验检疫科学研究院 一种用于快速检测新型h1n1流感病毒的双抗体夹心法
TWI620816B (zh) 2011-03-23 2018-04-11 苜蓿股份有限公司 植物衍生蛋白回收方法
AR088028A1 (es) 2011-08-15 2014-05-07 Boehringer Ingelheim Vetmed Proteinas h5, de h5n1 para un uso medicinal
JP6248040B2 (ja) * 2011-09-30 2017-12-13 メディカゴ インコーポレイテッド 植物における増加するウイルス様粒子収量
CN109265541A (zh) 2012-05-10 2019-01-25 麻省理工学院 流感中和药剂
CA2879228C (en) * 2012-07-17 2021-07-13 Merial Limited Attenuated swine influenza vaccines and methods of making and use thereof
KR101315273B1 (ko) * 2012-10-29 2013-10-08 대한민국 강독화된 인플루엔자 바이러스 변이주
CN104491463A (zh) * 2014-11-18 2015-04-08 四川金堂海纳生物医药技术研究所 一种治疗舌溢血(舌衄)的汤剂药物及制备方法
WO2016090297A1 (en) * 2014-12-04 2016-06-09 The New York Stem Cell Foundation Perfusion bioreactor
JOP20190088A1 (ar) 2016-10-21 2019-04-21 Us Agriculture نواقل مؤتلفة للتعبير عن مولدات مضاد فيروس انفلونزا الطيور و استخداماتها
US20180128545A1 (en) * 2016-11-08 2018-05-10 Berry Metal Company Modular furnace cooling wall
CN116075315A (zh) 2020-05-08 2023-05-05 刘扶东 嵌合流感疫苗
TW202334429A (zh) 2021-10-01 2023-09-01 中央研究院 Sars-cov-2棘蛋白特異性抗體及其用途
CN117229370A (zh) * 2022-06-08 2023-12-15 中科南京生命健康高等研究院 H5n6禽流感广谱性疫苗的开发及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5762939A (en) 1993-09-13 1998-06-09 Mg-Pmc, Llc Method for producing influenza hemagglutinin multivalent vaccines using baculovirus
EP0974660A1 (en) 1998-06-19 2000-01-26 Stichting Instituut voor Dierhouderij en Diergezondheid (ID-DLO) Newcastle disease virus infectious clones, vaccines and diagnostic assays
IL127331A0 (en) 1998-11-30 1999-09-22 Yeda Res & Dev Peptide-based vaccine for influenza
BRPI0410702B1 (pt) * 2003-05-28 2022-04-12 Wisconsin Alumni Research Foundation Composição, métodos para preparar um vírus de influenza e um veículo de liberação de genes, e, vírus
CN1261564C (zh) * 2003-12-02 2006-06-28 中国农业科学院哈尔滨兽医研究所 人工重组的流感病毒及其应用
US7871626B2 (en) 2005-08-04 2011-01-18 St. Jude Children's Research Hospital Modified influenza virus for monitoring and improving vaccine efficiency

Also Published As

Publication number Publication date
JP5395430B2 (ja) 2014-01-22
AU2006278696B2 (en) 2012-03-15
EP1924281B1 (en) 2019-05-08
KR20080042864A (ko) 2008-05-15
RU2011103648A (ru) 2012-08-10
CA2617483A1 (en) 2007-02-15
CN103172710B (zh) 2016-08-17
PL1924281T3 (pl) 2019-10-31
RU2552213C2 (ru) 2015-06-10
JP2009502197A (ja) 2009-01-29
US7871626B2 (en) 2011-01-18
ES2728791T3 (es) 2019-10-28
KR101334047B1 (ko) 2013-11-29
AU2006278696A1 (en) 2007-02-15
CN101283099A (zh) 2008-10-08
US8574592B2 (en) 2013-11-05
SG2014007934A (en) 2014-04-28
CA2617483C (en) 2016-09-27
UA94717C2 (ru) 2011-06-10
EP1924281A4 (en) 2014-01-01
US20130017216A1 (en) 2013-01-17
US9499850B2 (en) 2016-11-22
US8293247B2 (en) 2012-10-23
RU2480480C2 (ru) 2013-04-27
HUE043952T2 (hu) 2019-09-30
CN101283099B (zh) 2013-03-27
US20110104202A1 (en) 2011-05-05
BRPI0614297A2 (pt) 2011-03-22
EP1924281A2 (en) 2008-05-28
WO2007019094A3 (en) 2007-07-12
RU2420535C2 (ru) 2011-06-10
WO2007019094A2 (en) 2007-02-15
JP2014003982A (ja) 2014-01-16
AU2006278696A8 (en) 2008-03-06
US20070031453A1 (en) 2007-02-08
JP5745584B2 (ja) 2015-07-08
RU2013101020A (ru) 2014-07-20
US20140030702A1 (en) 2014-01-30
CN103172710A (zh) 2013-06-26
RU2008107875A (ru) 2009-09-10

Similar Documents

Publication Publication Date Title
SG2014007934A (en) Modified influenza virus for monitoring and improving vaccine efficiency
ZA200802892B (en) Vaccines and methods to treat canine influenza
SG2014012868A (en) Functional influenza virus like particles (vlps)
IL186611A0 (en) Vaccine against pandemic strains of influenza viruses
EP1603590A4 (en) INFLUENZA VIRUS VACCINE
IL189329A0 (en) Vaccination against dengue virus infection
IL182817A0 (en) Defective influenza virus particles
PT1942933E (pt) Vacinas contra a gripe canina
EP1855713A4 (en) GENERATED HORSE INFLUENZA VIRUS AND ITS USES
EP2091960A4 (en) PEPTIDE VACCINE AGAINST INFLUENZA VIRUS
IL196024A0 (en) Influenza vaccine
IL186710A (en) Influenza A virus is isolated from dogs, a drug and vaccine that include it and its use
EP2170382A4 (en) ATTENUATED INFLUENZA VIRUS AND LIVE VACCINE CONTAINING IT
SI2043682T1 (sl) Influenčno cepivo
AP2008004625A0 (en) Avian influenza viruses, vaccines, compositions, formulations, and methods
ZA200809056B (en) Influenza virus vaccine
BRPI0821034A2 (pt) Vírus influenza modificado
ZA200905952B (en) Lyophilized preparation comprising influenza vaccine,and method for preparation thereof
SI1951299T1 (sl) Cepiva proti influenci, ki vkljuäśujejo kombinacije adjuvantov iz delcev in imunopotenciatorjev
EP1856250A4 (en) NEW VACCINES LIVING VIRUSES
EP1871786A4 (en) PEPTIDE VACCINE AGAINST THE GRIPPEVIRUS
EP2054081A4 (en) VACCINE AGAINST THE JC VIRUS
GB0600081D0 (en) Chicken virus vaccine and diagnostic
ZA200802176B (en) Vaccination against dengue virus infection
ZA200703793B (en) Defective influenza virus particles